Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Biofrontera AG, DE0006046113

Biofrontera AG, DE0006046113

06.11.2019 - 11:35:25

Biofrontera AG: Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results

Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results Leverkusen, Germany, November 6, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the first nine months ended September 30, 2019 on November 19, 2019.

Conference calls for shareholders and interested investors will be held on November 19, 2019 at the following times:

In German, at 10:00 am CET (4:00 am ET) Dial-in number Germany: +49 69201744220 Conference code: 95804724#

In English, at 2:00 pm CET (8:00 am ET) Dial-in number USA: +1 8774230830 Dial-in number UK: +44 2030092470 Conference code: 49165242#

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.-End-

For enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer +49 (0) 214 87 63 2 0 ir@biofrontera.com IR UK: Seton Services Toni Vallen +44 (0) 207 229 0805 IR and PR US: The Ruth Group IR: Tram Bui PR: Kirsten Thomas +1 646-536-7035 +1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication XepiTM for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

06.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen

Germany Phone: +49 (0)214 87632 0 Fax: +49 (0)214 87632 90 E-mail: ir@biofrontera.com Internet: www.biofrontera.com ISIN: DE0006046113, NASDAQ: BFRA WKN: 604611 Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 905831   End of News DGAP News Service

905831  06.11.2019 

@ dgap.de